IP Library Granted Patent US 10,279,037
Granted Patent B2
US 10,279,037 · App. 15/584,822 · Granted May 7, 2019

Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules

Inventor: Isobel A. Scarisbrick (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K39/39558A61K31/7088A61K31/713A61K31/7105A61K38/4853C12N9/6445C12Y304/21008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,279,037
App. No.
15/584,822
Granted
May 7, 2019
Kind
B2
Abstract

This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.

Claims (5)

1. A method for increasing the susceptibility of cancer cells to apoptosis, wherein said cancer cells are present within a mammal and have Kallikrein 6 (KLK6) polypeptide-induced resistance to apoptosis, wherein said method comprises:

administering an inhibitor of KLK6 polypeptide expression to said mammal under conditions wherein said inhibitor reduces the level of KLK6 polypeptide-induced resistance to apoptosis triggered by an apoptosis-inducing agent of said cancer cells within said mammal, wherein said inhibitor is a KLK6 antisense molecule or a KLK6 miRNA molecule.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said method further comprises administering an additional anti-cancer agent to said mammal.

4. The method of claim 3 , wherein said additional anti-cancer agent is temozolomide, avastin, taxol, or radiation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: SCARISBRICK, ISOBEL A.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 042993/0434 →
CONFIRMATORY LICENSE Recorded May 15, 2017
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042463/0987 →
Continuity (4)
Division 13962686 · Aug 8, 2013
Division 13250599 · Sep 30, 2011
Provisional Application 61388289 · Sep 30, 2010
Related Publication 20170296660A1 · Oct 19, 2017